15 May 2017

THERMO FISHER SCIENTIFIC TO ACQUIRE PATHEON, A LEADING CONTRACT

Morrow Sodali

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. 

Morrow Sodali is serving as the proxy solicitor for Patheon N.V.

Topics

Recent Deals and Transactions Global USA